DNMT3A Mutation

CI-VAR-00002652Explore in graph →CIViC 189

Curated evidence

Evidence by cancer (7 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–7 of 7 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia4
DNMT3A Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID188 Young AML patients (415 patients; <60 years old) with any DNMT3A mutation (n=96) have shorter overall survival and relapse-free survival than patients with wildtype DNMT3A. PMID 22490330 · Ribeiro et al., 2012 · Open in CIViC	civic
DNMT3A Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID1585 In AML patients aged <60years, presence of a DNMT3A mutation associated with inferior CR rate (HR, 0.54; P=.05) and shorter OS (HR, 1.84; P<.001) in multivariate analyses. Mutated DNMT3A associated wi… (full text at CIViC) PMID 27288520 · Metzeler et al., 2016 · Open in CIViC	civic
DNMT3A Mutation

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Neoplasm1
DNMT3A Mutation	Atezolizumab + Nivolumab + PembrolizumabSubstitutes	Predictive	B	Supports Resistance	2	accepted	EID2926 A subset of patients receiving PD1/PD-L1 inhibition appear to be "hyper-progressors," with a greatly accelerated rate of tumor growth and clinical deterioration compared to pre-therapy. The current st… (full text at CIViC) PMID 28351930 · Kato et al., 2017 · Open in CIViC	civic

Myelodysplastic Syndrome1
DNMT3A Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID1238 12/150 patients with de novo myelodysplastic syndrome screened for DNMT3A mutations (bone marrow and paired normal skin) had heterozygous mutations with predicted translational consequences. 1 patient… (full text at CIViC) PMID 21415852 · Walter et al., 2011 · Open in CIViC	civic

T Acute Lymphoblastic Leukemia1
DNMT3A Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID469 In adult patients with early (n = 30), cortical (n = 30), mature (n = 3) or unknown (n = 8) T-cell acute lymphoblastic leukemia, those with mutations in DNMT3A (n=12) had shorter overall survival than… (full text at CIViC) PMID 23341344 · Grossmann et al., 2013 · Open in CIViC	civic